Hudson Valley Investment Advisors’s GSK GSK Stock Holding History

Hudson Valley Investment Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-4,466	Closed	-$210K	–	167
2020 Q3	$210K	Hold	4,466	–	–	0.05%	140
2020 Q2	$228K	Hold	4,466	–	–	0.05%	140
2020 Q1	$212K	Buy	4,466 +80	+2%	+$4.27K	0.06%	136
2019 Q4	$258K	Hold	4,386	–	–	0.06%	142
2019 Q3	$234K	Hold	4,386	–	–	0.05%	141
2019 Q2	$219K	Buy	4,386 +320	+8%	+$16.1K	0.05%	149
2019 Q1	$212K	Sell	4,066 -1,637	-29%	-$81.8K	0.05%	139
2018 Q4	$272K	Buy	+5,703	New	+$281K	0.06%	137
2018 Q3	–	Sell	-4,109	Closed	-$207K	–	154
2018 Q2	$207K	Hold	4,109	–	–	0.05%	140
2018 Q1	$201K	Buy	+4,109	New	+$191K	0.05%	139
2017 Q4	–	Sell	-4,706	Closed	-$239K	–	150
2017 Q3	$239K	Hold	4,706	–	–	0.06%	138
2017 Q2	$254K	Buy	+4,706	New	+$251K	0.07%	132

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

Hudson Valley Investment Advisors's GSK Position: Q4 2020 in Review

Hudson Valley Investment Advisors sold out of GSK (GSK) in Q4 2020, closing a stake of 4,466 shares — an estimated $210K sold.

Hudson Valley Investment Advisors first reported a position in GSK in Q2 2017 and held it in 12 quarters. The position peaked at $272K in Q4 2018. 818 funds tracked by Wall St. Rank hold GSK as of Q4 2020.

Hudson Valley Investment Advisors reported no remaining GSK position as of Q4 2020 after selling out during the quarter.
Hudson Valley Investment Advisors sold 4,466 GSK shares in Q4 2020, an estimated $210K.
Hudson Valley Investment Advisors first reported a position in GSK in Q2 2017 and held it in 12 quarters.
Hudson Valley Investment Advisors's GSK position peaked at $272K in Q4 2018.
818 funds tracked by Wall St. Rank held GSK as of Q4 2020.

Based on Hudson Valley Investment Advisors's 13F filing for Q4 2020, filed 15 Jan 2021.